This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic Stimulation

This study has been completed.
Sponsor:
Collaborator:
The Danish Multiple Sclerosis Society
Information provided by:
University of Aarhus
ClinicalTrials.gov Identifier:
NCT00342381
First received: June 20, 2006
Last updated: December 12, 2007
Last verified: December 2007
June 20, 2006
December 12, 2007
June 2006
Not Provided
  • Subjective fatigue (FSS) [ Time Frame: Weeks ]
  • Maximal voluntary isometric contraction, central activation before and after exercise [ Time Frame: at the time of investigation ]
  • Digit Symbol-Coding scores [ Time Frame: Weeks ]
  • Changes in normal appearing white matter and normal appearing gray matter (MRS-, MTI- and DTI- parameters) [ Time Frame: at the time of MRI ]
  • Cortical atrophy [ Time Frame: at the time of MRI ]
  • Intracortical inhibition/facilitation determined by transcranial magnetic stimulation (+/- 3,4-diaminopyridine) [ Time Frame: at the time of investigation ]
  • Subjective fatigue (FSS)
  • Maximal voluntary isometric contraction, central activation before and after exercise
  • Digit Symbol-Coding scores
  • Changes in normal appearing white matter and normal appearing gray matter (MRS-, MTI- and DTI- parameters)
  • Cortical atrophy
  • Cortical activity determined by fMRI (+/- 3,4 diaminopyridine)
  • Intracortical inhibition/facilitation determined by transcranial magnetic stimulation (+/- 3,4-diaminopyridine)
Complete list of historical versions of study NCT00342381 on ClinicalTrials.gov Archive Site
  • Subjective fatigue (MFI-20, Danish version) [ Time Frame: Weeks ]
  • Rapid voluntary twitches [ Time Frame: at the time of investigation ]
  • 6 minute walk test [ Time Frame: at the time of investigation ]
  • 9-hole peg test [ Time Frame: at the time of investigation ]
  • WAIS/WMS tests [ Time Frame: at the time of investigation ]
  • WHO-5 Questionnaire [ Time Frame: at the time of investigation ]
  • Major Depression Inventory [ Time Frame: at the time of investigation ]
  • Lesion load [ Time Frame: at the time of MRI ]
  • Whole brain atrophy [ Time Frame: at the time of MRI ]
  • Subjective fatigue (VAS) [ Time Frame: at the time of investigation ]
  • Subjective fatigue (MFI-20, Danish version)
  • Rapid voluntary twitches
  • 6 minute walk test
  • WAIS/WMS tests
  • WHO-5 Questionnaire
  • Major Depression Inventory
  • Lesion load
  • Whole brain atrophy
  • Subjective fatigue (VAS)
Not Provided
Not Provided
 
Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic Stimulation
Fatigue in Multiple Sclerosis: Evaluated With 3 Tesla MRI and Transcranial Magnetic Stimulation
The purpose of this study is to investigate fatigue in patients with multiple sclerosis (MS) and to determine the correlation between the symptom and cerebral changes.

Only recruiting from:

Department of Neurology, Aarhus University Hospital, Denmark

Interventional
Phase 2
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
  • Multiple Sclerosis
  • Fatigue
  • Drug: 3,4-diaminopyridine
    Single dose 3,4 diaminopyridine
  • Drug: Placebo
    Single dose placebo treatment
    Other Name: n/d
  • Active Comparator: 3.4 diaminopyridine
    Single dose 3,4 diaminopyridine
    Intervention: Drug: 3,4-diaminopyridine
  • Placebo Comparator: Placebo
    Two tablets identical to active treatment
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
120
December 2007
Not Provided

Inclusion Criteria:

  • Relapsing remitting-multiple sclerosis (RR-MS) according to Poser criteria
  • EDSS: max 3.5
  • Right handed
  • Normal function of the right hand

Exclusion Criteria:

  • Disease interfering with MS
  • Known dementia
  • Drug or alcohol abuse
  • Treatment with psychoactive drugs within one week before study entry
  • Major changes of medical treatment within 3 weeks before study entry
  • Attack within 4 weeks before study entry
  • Pregnancy
  • Conditions interfering with 3,4-diaminopyridine treatment
  • Conditions interfering with MRI
  • Conditions interfering with transcranial magnetic stimulation
Sexes Eligible for Study: All
18 Years to 55 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Denmark
 
 
NCT00342381
20060003
Yes
Not Provided
Not Provided
Henning Andersen, Dep of neurology, Aarhus University Hospital
University of Aarhus
The Danish Multiple Sclerosis Society
Principal Investigator: Henning Andersen, MD, DMSc Aarhus University Hospital, Aarhus Denmark
Study Chair: Johannes Jacobsen, Professor Aarhus University Hospital, Aarhus, Denmark
University of Aarhus
December 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP